These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38032175)

  • 1. Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.
    Kondili LA; Zanetto A; Quaranta MG; Ferrigno L; Panetta V; Calvaruso V; Zignego AL; Brunetto MR; Raimondo G; Biliotti E; Ieluzzi D; Iannone A; Madonia S; Chemello L; Cavalletto L; Coppola C; Morisco F; Barbaro F; Licata A; Federico A; Cerini F; Persico M; Pompili M; Ciancio A; Piscaglia F; Chessa L; Giacometti A; Invernizzi P; Brancaccio G; Benedetti A; Baiocchi L; Gentile I; Coppola N; Nardone G; Craxì A; Russo FP;
    United European Gastroenterol J; 2024 Apr; 12(3):352-363. PubMed ID: 38032175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response.
    Mandorfer M; Turon F; Lens S; Baiges A; García-Criado Á; Darnell A; Belmonte E; Ferrusquía-Acosta J; Magaz M; Perez-Campuzano V; Olivas P; Bauer D; Casanovas G; Torres F; Mariño Z; Forns X; Hernández-Gea V; García-Pagán JC
    Liver Int; 2021 Dec; 41(12):2954-2964. PubMed ID: 34242479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort.
    Kondili LA; Quaranta MG; Cavalletto L; Calvaruso V; Ferrigno L; D'Ambrosio R; Simonelli I; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Verucchi G; Massari M; Licata A; Barbaro F; Persico M; Russo FP; Morisco F; Pompili M; Viganò M; Puoti M; Santantonio T; Villa E; Craxì A; Chemello L;
    Dig Liver Dis; 2023 Jul; 55(7):907-917. PubMed ID: 36775720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    Atsukawa M; Tsubota A; Kondo C; Toyoda H; Takaguchi K; Nakamuta M; Watanabe T; Morishita A; Tani J; Okubo H; Hiraoka A; Nozaki A; Chuma M; Kawata K; Uojima H; Ogawa C; Asano T; Mikami S; Kato K; Matsuura K; Ikegami T; Ishikawa T; Tsuji K; Tada T; Tsutsui A; Senoh T; Kitamura M; Okubo T; Arai T; Kohjima M; Morita K; Akahane T; Nishikawa H; Iwasa M; Tanaka Y; Iwakiri K
    J Gastroenterol; 2024 Aug; 59(8):709-718. PubMed ID: 38727822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
    Calvaruso V; Celsa C; D'Ambrosio R; Simone F; Petta S; Cacciola I; Enea M; Battaglia S; Pandolfo A; Licata M; Degasperi E; Cabibbo G; Di Marco L; Pennisi G; Borghi M; Di Martino V; Filomia R; Abdel-Hadi Y; Crapanzano L; Raimondo G; Lampertico P; Craxì A; Cammà C; Di Marco V
    Am J Gastroenterol; 2022 Nov; 117(11):1816-1824. PubMed ID: 35973181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
    Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease.
    Giannini EG; De Maria C; Crespi M; Demarzo MG; Fazio V; Grasso A; Torre F; Bodini G; Marabotto E; Furnari M
    Eur J Clin Invest; 2020 May; 50(5):e13231. PubMed ID: 32291753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    Puigvehí M; Londoño MC; Torras X; Lorente S; Vergara M; Morillas RM; Masnou H; Serrano T; Miquel M; Gallego A; Lens S; Carrión JA
    J Gastroenterol; 2020 Feb; 55(2):205-216. PubMed ID: 31493238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.
    Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Hagiwara H; Oshita M; Imai Y; Hiramatsu N; Mita E; Kaneko A; Miyazaki M; Ohkawa K; Hijioka T; Fukui H; Ito T; Yamamoto K; Doi Y; Yoshida Y; Yamada Y; Yakushijin T; Tatsumi T; Takehara T;
    Dig Dis Sci; 2023 May; 68(5):2115-2122. PubMed ID: 36526814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients.
    Zampino R; Lebano R; Coppola N; Macera M; Grandone A; Rinaldi L; De Sio I; Tufano A; Stornaiuolo G; Adinolfi LE; Durante-Mangoni E; Battista GG; Niglio A
    Saudi J Gastroenterol; 2018; 24(1):25-29. PubMed ID: 29451181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
    J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
    Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
    Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preoperative risk factors of portal venous thrombosis after splenectomy and gastric pericardial devascularization for portal hypertension].
    Han J; Yi Y; Ding H; Liu J; Zhang Y; Hu L; Zhao L; Liu T
    Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):739-43. PubMed ID: 25496862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
    Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
    J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.
    Casadei Gardini A; Foschi FG; Conti F; Petracci E; Vukotic R; Marisi G; Buonfiglioli F; Vitale G; Ravaioli F; Gitto S; Verucchi G; Lenzi M; Bolondi L; Mazzella G; Brillanti S; Andreone P;
    Dig Liver Dis; 2019 May; 51(5):681-688. PubMed ID: 30327251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
    Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
    Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.